Drug interactions in HIV-infected patients treated for hepatitis C

Expert Opinion on Drug Metabolism and Toxicology

Volumn 13, Issue 8, 2017, Pages 807-816

  Soriano, Vicente ^a   Labarga, Pablo ^b   Fernandez Montero, José V ^c   Mendoza, C d ^d   Benítez Gutiérrez, Laura ^d   Peña, José M ^a   Barreiro, Pablo ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b La Luz Clinic ^*  (Spain)

^c CROSSHOUSE HOSPITAL   (United Kingdom)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

antiretroviral therapy; daclatasvir; dolutegravir; drug interactions; elbasvir; grazoprevir; HCV; HIV; Sofosbuvir; velpatasvir

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; DACLATASVIR; DIRECT ACTING ANTIVIRAL AGENT; ELBASVIR; GRAZOPREVIR; LEDIPASVIR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; NONSTRUCTURAL PROTEIN 5B; OMBITASVIR; PARITAPREVIR; RNA DIRECTED RNA POLYMERASE INHIBITOR; SIMEPREVIR; UNCLASSIFIED DRUG; VELPATASVIR;

ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; NONHUMAN; REVIEW; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG INTERACTION; DRUG MONITORING; HIV INFECTIONS; PROCEDURES;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; COINFECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG MONITORING; HEPATITIS C; HIV INFECTIONS; HUMANS;

EID: 85026247150     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1080/17425255.2017.1351942     Document Type: Review

References (83)

1. WHO/UNAIDS working group on global HIV/AIDS and STI surveillance. [cited 2017 Jan 5]. Available from:http://www.who.int/hiv/data/epi
2. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:45–57.
3. Ly K, Xing J, Klevens R, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156:271–278.
4. Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV:a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16:797–808.
5. Barreiro P, Fernandez-Montero JV, De Mendoza C, et al. Towards hepatitis C eradication from the HIV-infected population. Antiviral Res. 2014;105:1–7.
6. Soriano V, Labarga P, De Mendoza C, et al. Acute hepatitis C virus re-infection in a heterosexual HIV-positive partner. Liver Int. 2016;36:763.
7. Schmidt A, Rockstroh J, Vogel M, et al. Trouble with bleeding:risk factors for acute hepatitis C among HIV-positive gay men from Germany - a case-control study. PLoS One. 2011;6:e17781.
8. Sánchez C, Plaza Z, Vispo E, et al. Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain. Liver Int. 2013;33:1357–1362.
9. Soriano V, Perelson A, Zoulim F., Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother. 2008;62:1–4.
10. Fernandez-Montero JV, Eugenia E, Barreiro P, et al. Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management. Expert Opin Drug Saf. 2013;12:697–707.
11. DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. [cited 2017 Apr 21]. Available from:http://aidsinfo.nih.gov/e-news
12. European AIDS Clinical Society Guidelines. Clinical management and treatment of HIV infected adults in Europe. 2016 Oct [cited 2017 Apr21]. Available from:http://www.eacsociety.org/Portals/0/GUIDELINES/
13. Llibre JM, Clotet B., Once-daily single-tablet regimens:a long and winding road to excellence in antiretroviral treatment. AIDS Rev. 2012;14:168–178.
14. Podzamczer D, Andrade-Villanueva J, Clotet B, et al. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). HIV Med. 2011;12:374–382.
15. Blanco F, Barreiro P, Ryan P, et al. Risk factors for advanced liver fibrosis in HIV-infected individuals:role of antiretroviral drugs and insulin resistance. J Viral Hepat. 2011;18:11–16.
16. Lawitz E, Sulkowski M, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with HCV genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients:the COSMOS randomised study. Lancet. 2014;384:1756–1765.
17. Sulkowski M, Gardiner D, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–221.
18. Kowdley K, Gordon S, Reddy K, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–1888.
19. IDSA/AASLD. Recommendations for testing, managing, and treating hepatitis C. [cited 2017 Jan 5]. Available from:http://www.hcvguidelines.org• This free website provides time frame updated information on the recommended antiviral regimens for treating hepatitis C by the USA Hepatology and Infectious Diseases societies.
20. EASL. Recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153–194.• This article provides updated information on the recommended antiviral regimens for treating hepatitis C in Europe.
21. Foster G, Afdhal N, Roberts S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–2617.
22. Terrault N. Difficult-to-cure populations with chronic hepatitis C:vanishing in the direct-acting antiviral era? Hepatology. 2015;62:4–7.
23. Toussaint-Miller K, Andres J. A special touch:treatment considerations for unique patient populations with HCV genotype 1 infection. Ann Pharmacother. 2015;49:1015–1030.
24. Molina JM, Orkin C, Iser D, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2):a multicentre, open-label, non-randomised, phase 3 study. Lancet. 2015;385:1098–1106.
25. Sulkowski M, Eron J, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1:a randomized trial. Jama. 2015;313:1223–1231.
26. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. Jama. 2015;313:1232–1239.
27. Kaur K, Gandhi M, Slish J. Drug-drug interactions among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) medications. Infect Dis Ther. 2015;4:159–172.
28. Lo Re V, Kallan M, Tate J, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients:a cohort study. Ann Intern Med. 2014;160:369–379.
29. Labarga P, Fernandez-Montero JV, Lopez M, et al. Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies. Antivir Ther. 2014;19:799–803.
30. Fernandez-Montero JV, Vispo E, Barreiro P, et al. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. Clin Infect Dis. 2014;58:1549–1553.
31. Lee M, Yang H, Lu S, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases:a community-based long-term prospective study. J Infect Dis. 2012;206:469–477.
32. Soriano V, Labarga P, Fernandez-Montero JV, et al. Hepatitis C cure with antiviral therapy - benefits beyond the liver. Antivir Ther. 2016;21:1–8.
33. 3 compared with the general population:evidence from a large European observational cohort collaboration. Int J Epidemiol. 2012;41:433–445.
34. Gallego L, Barreiro P, Del Río R, et al. Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz. Clin Infect Dis. 2004;38:430–432.
35. Muñoz-Moreno J, Fumaz C, Ferrer M, et al. Neuropsychiatric symptoms associated with efavirenz:prevalence, correlates and management. A neurobehavioral review. AIDS Rev. 2009;11:103–109.
36. Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients:a systematic review. AIDS Rev. 2010;12:67–75.• This is an excellent review about the neurocognitive and psychiatric disorders associated to efavirenz therapy.
37. Jiménez-Nácher I, Alvarez E, Morello J, et al. Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. Expert Opin Drug Metab Toxicol. 2011;7:457–477.
38. Leslie E, Deeley R, Cole S. Multidrug resistance proteins:role of p-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005;204:216–237.
39. Wessler J, Grip L, Mendell J, et al. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol. 2013;61:2495–2502.
40. Chtioui H, Buclin T, Moradpour D. New hepatitis C treatments:pharmacological considerations and potential for drug interactions. Rev Med Suisse. 2014;10:1600–1604.
41. MacBrayne C, Kiser J. Pharmacologic considerations in the treatment of hepatitis C virus in persons with HIV. Clin Infect Dis. 2016;63(suppl 1):12–23.
42. Bunnell K, Vibhakar S, Glowacki R, et al. Nephrotoxicity associated with concomitant use of ledipasvir-sofosbuvir and tenofovir in a patient with hepatitis C virus and human immunodeficiency virus coinfection. Pharmacotherapy. 2016;36:e148–53.
43. Khatri A, Dutta S, Dunbar M, et al. Evaluation of drug-drug interactions between direct-acting Anti-Hepatitis C Virus combination regimens and the HIV-1 antiretroviral agents raltegravir, tenofovir, emtricitabine, efavirenz, and rilpivirine. Antimicrob Agents Chemother. 2016;60:2965–2971.
44. Ahmad T, Yin P, Saffitz J, et al. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology. 2015;62:409–416.•• This is the first report of patients the experienced bradychardia using sofosbuvir and amiodarone.
45. Back D, Else L. The importance of drug-drug interactions in the DAA era. Dig Liver Dis. 2013;45(suppl):343–348.
46. Soriano V, Labarga P, Barreiro P, et al. Drug interactions with new hepatitis C oral drugs. Exp Opin Drug Metab Toxicol. 2015;11:333–341.
47. Karageorgopoulos D, El-Sherif O, Bhagani S, et al. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. Curr Opin Infect Dis. 2014;27:36–45.•• This is a comprehensive and updated review on the major drug–drug interactions between antivirals in HIV–HCV-coinfected patients.
48. Burger D, Back D, Buggisch P, et al. Clinical management of drug-drug interactions in HCV therapy:challenges and solutions. J Hepatol. 2013;58:792–800.•• This is a pivotal review on major drug–drug interactions of new oral HCV drugs, written by pharmacologists with large expertise in antivirals and robust clinical knowledge.
49. Kiser J, Burton J, Everson G. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10:596–606.• This review summarizes the most relevant information on mechanisms of drug interactions expected and/or clinically observed using new oral hepatitis C drugs.
50. Burgess S, Partovi N, Yoshida E, et al. A review of drug interactions with direct-acting antivirals for hepatitis C:implications for HIV and transplant patients. Ann Pharmacother. 2015;49:674–687.•• This is a comprehensive review on drug interactions between DAA and either ARV or immunosuppressants.
51. Flanagan S, Crawford-Jones A, Orkin C. Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection. Expert Rev Clin Pharmacol. 2014;7:691–704.
52. Bonora S, Puoti M. Use of daclatasvir in HCV/HIV-Coinfected patients in a real-life setting. AIDS Rev. 2017;19:24–34.
53. Merli M, Galli L, Marinaro L, et al. Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. J Antimicrob Chemother. 2017;72:812–815.
54. Reese M, Savina P, Generaux G, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013;41:353–361.
55. Sarrazin C, Lathouwers E, Peeters M, et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res. 2015;116:10–16.
56. Soriano V, Barreiro P, De Mendoza C, et al. Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child-Pugh B compensated cirrhosis. Antivir Ther. 2016;21:91–92.
57. Kwo P, Badshah M. New hepatitis C virus therapies:drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease. Curr Opin Organ Transplant. 2015;20:235–241.
58. Minaei A, Kowdley K. ABT-450/ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus. Expert Opin Pharmacother. 2015;16:929–937.
59. Dore G, Altice F, Litwin A, et al. Elbasvir-Grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy:a randomized trial. Ann Intern Med. 2016;165:625–634.
60. Cholongitas E, Papatheodoridis G. Sofosbuvir:a novel oral agent for chronic hepatitis C. Ann Gastroenterol. 2014;27:331–337.
61. Koff R. The efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2014;39:478–487.
62. Ferenci P. Treatment of hepatitis C in difficult-to-treat patients. Nat Rev Gastroenterol Hepatol. 2015;12:284–292.
63. Fazel Y, Lam B, Golabi P, et al. Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. Expert Opin Drug Saf. 2015;14:1317–1326.
64. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. Aids. 2009;23:689–696.
65. Wang H, Lu X, Yang X, et al. The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy:meta-analysis. Medicine (Baltimore). 2016;95:e5146.
66. Paré G, Eriksson N, Lehr T, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013;127:1404–1412.
67. Bunchorntavakul C, Reddy K. The efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2015;42:258–272.
68. Bifano M, Hwang C, Oosterhuis B, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents:ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther. 2013;18:931–940.
69. Coppola N, Martini S, Pisaturo M, et al. Treatment of chronic hepatitis C in patients with HIV/HCV coinfection. World J Virol. 2015;4:1–12.
70. Alqahtani S, Afdhal N, Zeuzem S, et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection:analysis of phase III ION trials. Hepatology. 2015;62:25–30.
71. Mogalian E, German P, Kearney B, et al. Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir. Clin Pharmacokinet. 2016;55:605–613.
72. Kwo P, Gane E, Peng C, et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2017;152:164–175.
73. Gane E, Poordad F, Wang S, et al. High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis. Gastroenterology. 2016;151:651–659.
74. Tong L, Yu W, Chen L, et al. The discovery of ruzasvir (MK-8408):a potent, pan-genotype HCV NS5A inhibitor with optimized activity against common resistance-associated polymorphisms. J Med Chem. 2017;60:290–306.
75. Kwo P, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. Forthcoming.
76. Jacobson I, Lawitz E, Gane E, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection:2 phase 3 randomized trials. Gastroenterology. 2017;153:113–122.
77. Macías J, Monge P, Mancebo M, et al. High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice. HIV Med. Forthcoming.
78. Martinello M, Dore G, Skurowski J, et al. Antiretroviral use in the CEASE cohort study and implications for direct-acting antiviral therapy in human immunodeficiency virus/hepatitis C virus coinfection. Open Forum Infect Dis. 2016;3:ofw105.
79. Crauwels H, van Heeswijk R, Stevens M, et al. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. AIDS Rev. 2013;15:87–101.
80. Ripamonti D, Bombana E, Rizzi M. Rilpivirine:drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor. Expert Rev Anti Infect Ther. 2014;12:13–29.
81. Binda C, Tortora A, Garcovich M, et al. Toxicity and risks from drug-to-drug interactions of new antivirals for chronic hepatitis C. Eur Rev Med Pharmacol Sci. 2017;21(1 Suppl):102–111.
82. Singh H, Del Carmen T, Freeman R, et al. From one syndrome to many:incorporating geriatric consultation into HIV care. Clin Infect Dis. Forthcoming.
83. Sasadeusz J. HIV and HCV therapies in 2016:optimal regimens. AIDS Rev. 2016;18:212–221.